Surgery aftercare for non-clear kidney cancer at high risk
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18–75 years old.
- Have a confirmed diagnosis of non-clear renal cell carcinoma (not clear cell, chromophobe, or eosinophilic).
- Have had surgery to completely remove the main kidney tumor (partial or full kidney removal is allowed), and surgery must be done at least 3 weeks but no more than 12 weeks before randomization.
- After surgery, imaging must show no visible remaining cancer; if you had metastases (M1), they must have been completely removed and you must have no evidence of disease (M1 NED).
- Not have started any prior whole-body (systemic) cancer treatment for kidney cancer, and have enough blood counts, liver/kidney function, and heart function to safely take study drugs. (You’ll be checked with blood tests and heart scans.)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and targeted drugs (called IO/TKI) given before and after surgery for clear cell renal cell carcinoma (a type of kidney cancer). The goal is to shrink tumors and improve survival outcomes.
This trial tests whether the drug toripalimab can prevent kidney cancer from coming back in people who have had their kidney and any visible metastases surgically removed. It focuses on patients with high-risk features or who had some metastatic spots taken out completely.
This trial tests whether giving immunotherapy before surgery can help people with advanced kidney cancer. The goal is to see if waiting on surgery and starting with medication that boosts the immune system is safe and effective.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
This trial tests whether the drug pembrolizumab, given after surgery to remove kidney cancer, can help prevent the cancer from coming back. Pembrolizumab helps your immune system fight cancer cells.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
Hear when a new Non-clear Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.